Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | TYMP | P19971 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | ST6GAL1 | P15907 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CDA | P32320 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2401695 | 1.00 | LMNA (0.52) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL9044857 | 0.90 | LMNA (0.56) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL5505015 | 0.90 | TYMP (0.51) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL5505017 | 0.90 | TYMP (0.51) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL1737308 | 0.86 | TYMP (0.54) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL5710025 | 0.83 | TYMP (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL17223094 | 0.83 | TYMP (0.51) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL1054903 | 0.81 | LMNA (0.68) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL1054900 | 0.81 | LMNA (0.68) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL31390283 | 0.81 | TYMP (0.49) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026349-B2 | Polynucleotide synthesis labeling chemistry | DHARMACON, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20080009612-A1 | Novel Polynucleotide Synthesis Labeling Chemistry | DHARMACON, INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009612-A1 | Novel Polynucleotide Synthesis Labeling Chemistry | POLN, POLRMT, POLM | LMNA 269/4885THRB 4661/4885MTOR 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.